Add this topic to your myFT Digest for news straight to your inbox
Research is finding ways to extend animal lifespans but regulators are still wary of treating ageing as a disease
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Success of biosimilars in lowering prices will depend on decisions from powerful pharmacy benefit managers
Biosecure Act would prohibit American companies receiving federal grant money from working with some Chinese groups
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Neglecting women’s pain affects the entire medical pipeline, from research to diagnosis and treatment
Admonitions about staff trading in their employer’s shares may now need to be broadened
Judge to decide on admission of evidence as part of litigation that has knocked billions off pharma group’s value
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
WPP-owned advertising agency seeks to tap trend for seeking medical information on social media
Technique highlights concerns shifting global disease burden as populations age
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Factory inspectors refuse to visit country over fears they could fall foul of tightened rules
Report from Nuffield Trust health think-tank highlights impact of leaving EU on medicine supply chains
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
GQG Partners argues that pharma group has performed strongly under long-serving chief
International Edition